The Zacks Analyst Blog Highlights: Johnson & Johnson, GlaxoSmithKline, Pfizer and Gilead Sciences - wistv.com - Columbia, South Carolina |

The Zacks Analyst Blog Highlights: Johnson & Johnson, GlaxoSmithKline, Pfizer and Gilead Sciences

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Zacks Investment Research, Inc.

CHICAGO, June 16, 2014 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Johnson & Johnson (NYSE:JNJ-Free Report), GlaxoSmithKline (NYSE:GSK-Free Report), Pfizer (NYSE:PFE-Free Report) and Gilead Sciences (Nasdaq:GILD-Free Report).

Zacks Investment Research, Inc., www.zacks.com

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

Here are highlights from Friday's Analyst Blog:

J&J, ViiV Healthcare Tie Up for Single-Tablet HIV Treatment

ViiV Healthcare has entered into an agreement with Janssen R&D Ireland Ltd., a subsidiary of Johnson & Johnson (NYSE:JNJ-Free Report), for the development and commercialization of a single tablet combination of ViiV Healthcare's Tivicay and Johnson & Johnson's Edurant.

ViiV Healthcare, a company focused on the treatment of HIV, was established by GlaxoSmithKline (NYSE:GSK-Free Report) and Pfizer (NYSE:PFE-Free Report) in 2009. After certain amendments in Oct 2012, Glaxo, Pfizer and Shionogi now own 76.5%, 13.5% and 10% of ViiV Healthcare, respectively.

The Johnson & Johnson agreement is in line with ViiV Healthcare's strategy to develop Tivicay-based therapies. We remind investors that Tivicay was cleared by the FDA in Aug 2013 as an add-on therapy to other antiretroviral agents for the treatment of patients suffering from HIV-1, who are above 12 years and weigh at least 88 lbs.

ViiV Healthcare and Johnson & Johnson plan to initiate studies on a single-tablet combination of Tivicay and Edurant by the first quarter of 2015. The companies are looking to evaluate the combination as an HIV maintenance therapy for patients already virally suppressed on a three-drug regimen.

Additionally, the companies will evaluate a fixed-dose combination of Tivicay and Edurant in pediatric patients. We note that the pediatric patient population represents an unmet disease area with approximately 3.3 million children living with HIV globally of which approximately 2.2 million children (66%) do not have access to appropriate care and medicines.

Johnson & Johnson, Glaxo and Pfizer are all Zacks Rank #3 (Hold) stocks. A better-ranked stock in the health care sector is Gilead Sciences (Nasdaq:GILD-Free Report) carrying a Zacks Rank #1 (Strong Buy).

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today.

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros.  In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.

Get the full Report on JNJ - FREE

Get the full Report on GSK - FREE

Get the full Report on PFE - FREE

Get the full Report on GILD - FREE

Follow us on Twitter: http://twitter.com/zacksresearch

Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com

http://www.zacks.com

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Logo - http://photos.prnewswire.com/prnh/20101027/ZIRLOGO

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow